Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.52 |
| ▸ | FAAH | O00519 | 5/20 | 0.46 |
| ▸ | CES1 | P23141 | 5/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 5/20 | 0.38 |
| ▸ | CA9 | Q16790 | 5/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5074174 | 0.98 | CA2 (0.56) | CA2FAAHCES1CES2CA1 | |
| SCHEMBL5076177 | 0.98 | CA2 (0.56) | CA2FAAHCES1CES2CA1 | |
| SCHEMBL2047865 | 0.95 | CA2 (0.52) | CA2FAAHCES1CES2CA1 | |
| SCHEMBL7858048 | 0.93 | CA2 (0.50) | CA2FAAHCES1CES2CA1 | |
| SCHEMBL5667637 | 0.90 | CA2 (0.52) | CA2FAAHCES1CES2ESR1 | |
| SCHEMBL5387890 | 0.88 | CA2 (0.56) | CA2FAAHCES1CES2ESR1 | |
| SCHEMBL8957646 | 0.88 | CA2 (0.56) | CA2FAAHCES1CES2ESR1 | |
| SCHEMBL10587432 | 0.88 | CA2 (0.56) | CA2FAAHCES1CES2ESR1 | |
| SCHEMBL3033925 | 0.88 | CA2 (0.45) | CA2FAAHCES1CES2ESR1 | |
| SCHEMBL148338 | 0.87 | CA2 (0.43) | CA2FAAHCES1CES2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2343299-B9 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2017-03-08 | — | — | EP | claimed |
| CN-116199612-B | Porous adsorbent and preparation method and application thereof | 荆楚理工学院 | 2024-06-21 | — | — | CN | disclosed |
| CN-220331802-U | Injection mold, insulator spacer and insulator for switchgear | 日立能源有限公司 | 2024-01-12 | — | — | CN | disclosed |
| US-9732221-B2 | Reinforced thermoplastic resin composition and molded article | UMG ABS, LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| US-9725591-B2 | Reinforced resin composition for plating base, molded article, and electroplated component | UMG ABS, LTD. (JP) | 2017-08-08 | — | — | US | disclosed |
| US-20170037244-A1 | Reinforced Thermoplastic Resin Composition And Molded Article | UMG ABS, LTD. (JP) | 2017-02-09 | — | — | US | disclosed |
| US-9309404-B2 | Reinforced thermoplastic resin composition and molded article | UMG ABS, LTD. (JP) | 2016-04-12 | — | — | US | disclosed |
| US-20150322261-A1 | Reinforced Thermoplastic Resin Composition And Molded Article | UMG ABS, LTD. (JP) | 2015-11-12 | — | — | US | disclosed |
| US-8877854-B2 | Reinforced thermoplastic resin composition and molded article | UMG ABS, LTD. (JP) | 2014-11-04 | — | — | US | disclosed |
| US-8536248-B2 | Reinforced thermoplastic resin composition and molded article | UMG ABS, LTD. (JP) | 2013-09-17 | — | — | US | disclosed |
| CN-101522806-A | Flame-retardant polycarbonate resin composition, polycarbonate resin molded article, and method for producing same | IDEMITSU KOSAN CO (JP) | 2009-09-02 | — | — | CN | disclosed |
| WO-2005040112-A1 | COMPOUNDS WITH PGD2 ANTAGONIST ACTIVITY | OXAGEN LIMITED (GB) | 2005-05-06 | — | — | WO | disclosed |
| US-6559174-B2 | For therapy of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis | MERCK & CO., INC. | 2003-05-06 | — | — | US | disclosed |
| US-6512077-B1 | Polycarbonate-base flame-retardant resin composition | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2003-01-28 | — | — | US | disclosed |
| US-20020193399-A1 | N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors | MERCK & CO., INC. | 2002-12-19 | — | — | US | disclosed |
| US-6486241-B2 | POLYMER ALLOY; WATERPROOFING, AGING RESISTANCE | GENERAL ELECTRIC COMPANY | 2002-11-26 | — | — | US | disclosed |
| US-20020161111-A1 | POLYCARBONATE RESIN COMPOSITION | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2002-10-31 | — | — | US | disclosed |
| EP-1007593-B1 | POLYCARBONATE RESIN COMPOSITION | GEN ELECTRIC (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1007593-A1 | POLYCARBONATE RESIN COMPOSITION | GENERAL ELECTRIC COMPANY (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999011713-A1 | POLYCARBONATE RESIN COMPOSITION | GENERAL ELECTRIC COMPANY (US) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193399-A1 | N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors | VCAM1, CD4, ITGA4 | CA2 4803/4885FAAH 1546/4885CES1 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.